FY2026 Earnings Estimate for uniQure Issued By HC Wainwright

uniQure N.V. (NASDAQ:QURE – Free Report) – Investment analysts at HC Wainwright boosted their FY2026 earnings per share estimates for shares of uniQure in a note issued to investors on Wednesday, November 18th. HC Wainwright analyst P. Trucchio now forecasts that the biotechnology company will earn ($3.79) per share for the year, up from their previous forecast of ($3.98). HC Wainwright has a “Buy” rating and a $65.00 price objective on the stock. The consensus estimate for uniQure’s current full-year earnings is ($3.79) per share. HC Wainwright also issued estimates for uniQure’s Q4 2026 earnings at ($0.84) EPS, Q1 2027 earnings at ($0.88) EPS, Q2 2027 earnings at ($0.92) EPS, Q3 2027 earnings at ($0.81) EPS, Q4 2027 earnings at ($0.70) EPS, FY2027 earnings at ($3.31) EPS, FY2028 earnings at ($0.96) EPS, FY2029 earnings at $1.48 EPS and FY2030 earnings at $3.87 EPS.

Other equities research analysts have also recently issued reports about the company. Weiss Ratings upgraded uniQure from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, September 21st. Barclays lowered shares of uniQure from an “overweight” rating to an “equal weight” rating and cut their price target for the stock from $60.00 to $28.00 in a report on Monday, October 5th. Wall Street Zen raised shares of uniQure from a “sell” rating to a “hold” rating in a research note on Saturday, November 7th. The Goldman Sachs Group dropped their price target on shares of uniQure from $46.00 to $31.00 and set a “neutral” rating for the company in a research note on Wednesday, September 30th. Finally, Wolfe Research raised uniQure from a “peer perform” rating to an “outperform” rating and set a $65.00 price objective for the company in a research note on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $55.58.

Check Out Our Latest Analysis on QURE

uniQure Stock Down 4.3%

Shares of uniQure stock opened at $19.35 on Friday. uniQure has a 1 year low of $8.73 and a 1 year high of $51.72. The firm’s 50-day moving average is $27.05 and its two-hundred day moving average is $29.58. The stock has a market cap of $1.36 billion, a price-to-earnings ratio of -5.51 and a beta of 1.14. The company has a debt-to-equity ratio of 0.17, a current ratio of 11.52 and a quick ratio of 11.52.

uniQure (NASDAQ:QURE – Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported ($0.88) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.04. uniQure had a negative net margin of 1,154.84% and a negative return on equity of 96.34%. The company had revenue of $5.20 million during the quarter, compared to analyst estimates of $6.17 million.

Institutional Trading of uniQure

A number of institutional investors have recently added to or reduced their stakes in QURE. Seven Fleet Capital Management LP acquired a new position in shares of uniQure in the second quarter worth $15,254. IFP Advisors Inc boosted its holdings in shares of uniQure by 39.8% in the 2nd quarter. IFP Advisors Inc now owns 2,780 shares of the biotechnology company’s stock valued at $128,000 after purchasing an additional 791 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in uniQure during the third quarter valued at about $86,000. Fulton Bank N.A. purchased a new stake in shares of uniQure during the 2nd quarter worth about $220,000. Finally, Activest Wealth Management acquired a new stake in shares of uniQure in the third quarter worth $121,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

Key Headlines Impacting uniQure

Investors following QURE have been watching these headlines:

  • Positive Sentiment: HC Wainwright raised its estimates for FY2026 and FY2027, as well as several quarterly forecasts, indicating smaller expected losses. The firm kept its Buy rating. Analyst estimate details
  • Neutral Sentiment: Analyst coverage cited an average price target of $56.83, though that figure alone does not indicate a new change in sentiment. Average price target report
  • Negative Sentiment: HC Wainwright cut its price target to $65 and lowered its FY2029 and FY2030 earnings estimates, tempering the more favorable near-term revisions. It nevertheless retained its Buy rating. Price target report Target cut coverage

About uniQure

(Get Free Report)

uniQure N.V. is a biotechnology company that develops gene therapies for serious genetic and other diseases. The company uses adeno-associated virus (AAV) vectors to deliver genetic material to patients’ cells, with research and development operations in the United States and the Netherlands. Its programs have targeted conditions including Huntington’s disease, epilepsy and hemophilia B. uniQure developed the gene therapy now known as Hemgenix for hemophilia B; it is commercialized by CSL Behring under a partnership.

See Also

Earnings History and Estimates for uniQure (NASDAQ:QURE)

Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.